ICLR
NASDAQ HealthcareICON plc - Ordinary Shares
Diagnostics & Research
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, contract staffing, data solutions, and laboratory services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers testing services comprising bioanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, medical imaging, real world intelligence, site and patient, and strategic solutions. Additionally, it provides therapeutics for cardiovascular, central nervous system, endocrine and metabolic disorders, hepatology, infectious diseases, internal medicine immunology, and oncology. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.
๐ Market Data
| Price | $169.45 |
|---|---|
| Volume | 477,717 |
| Market Cap | 13.07B |
| Beta | 1.200 |
| RSI (14-Day) | 39.3 |
| 200-Day MA | $147.07 |
| 50-Day MA | $162.51 |
| 52-Week High | $203.91 |
| 52-Week Low | $66.57 |
| P/E Ratio | 260.69 |
| Forward P/E | 14.27 |
| Price / Book | 1.39 |
๐ฏ Investment Strategy Scores
ICLR scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Moon Shot (79/100) โ this strategy High growth potential (high beta + oversold).
Lowest fit among scored strategies: ๐ Over-Hyped (19/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find ICLR in your text
Paste any article, transcript, or post โ the tool will extract ICLR and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-08-17.